These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22261589)

  • 1. Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei.
    Pillai K; Akhter J; Chua TC; Morris DL
    J Surg Res; 2012 May; 174(2):e69-73. PubMed ID: 22261589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
    Pillai K; Akhter J; Chua TC; Morris DL
    Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.
    Pillai K; Akhter J; Chua TC; Morris DL
    Invest New Drugs; 2012 Oct; 30(5):2080-6. PubMed ID: 22359216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomyxoma peritonei: does a true mucolytic agent exist? In vitro and in vivo studies.
    Shyr YM; Su CH; Wang HC; Lo SS; Lui WY
    Am Surg; 1995 Mar; 61(3):265-70. PubMed ID: 7887544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC2 is a molecular marker for pseudomyxoma peritonei.
    O'Connell JT; Hacker CM; Barsky SH
    Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer.
    Miyashita T; Murata K; Hoshino E; Nishiya H; Ono Y; Akaoka I; Kunii O
    Dig Dis Sci; 1999 Nov; 44(11):2231-4. PubMed ID: 10573367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.
    Akhter J; Pillai K; Chua TC; Alzarin N; Morris DL
    Am J Cancer Res; 2014; 4(5):495-507. PubMed ID: 25232491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
    Hsu KH; Chou CY; Chang YC
    Hepatogastroenterology; 2007; 54(73):47-52. PubMed ID: 17419229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
    Chua TC; Akther J; Yao P; Morris DL
    Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
    Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
    Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
    Smeenk RM; Verwaal VJ; Zoetmulder FA
    Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
    Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
    Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of pseudomyxoma peritonei with a pancreatic cancer treated by the intraperitoneal administration of cisplatinum].
    Mitsuhashi T; Murata N; Sobajima J; Okada N; Suzuki T; Ishida H; Hashimoto D; Miura I; Itoyama S
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1670-3. PubMed ID: 11708005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
    Sasaki A; Terashima M; Okamoto K; Ikeda K; Takagane A; Takiyama I; Kuboi M; Sasaki N; Saito K
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1571-4. PubMed ID: 8854808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavage.
    Piver MS; Lele SB; Patsner B
    Obstet Gynecol; 1984 Sep; 64(3 Suppl):95S-96S. PubMed ID: 6472756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomyxoma peritonei: a clinicopathologic analysis and follow-up of 21 patients.
    Varona JF; Guerra JM; Salamanca J; Colina F; Lopez G; Morales M
    Hepatogastroenterology; 2005; 52(63):812-6. PubMed ID: 15966210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of pseudomyxoma peritonei is developing].
    Lepistö A; Osterlund P; Järvinen HJ
    Duodecim; 2010; 126(14):1693-9. PubMed ID: 20804088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pseudomyxoma peritonei].
    Andreassen G
    Tidsskr Nor Laegeforen; 1995 Sep; 115(22):2783. PubMed ID: 7570495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.